{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:02:38Z","timestamp":1761663758268,"version":"3.37.3"},"reference-count":101,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2017.0011","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:29:13Z","timestamp":1525253353000},"source":"Crossref","is-referenced-by-count":12,"title":["Treatment Options in Hepatitis C"],"prefix":"10.3238","author":[{"given":"Stefan","family":"Zeuzem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2017,1,9]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Poordad F, Schiff ER, Vierling JM, et al.: Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016; 63: 1493\u20131505","key":"10.3238\/arztebl.2017.0011_ref1","DOI":"10.1002\/hep.28446"},{"doi-asserted-by":"crossref","unstructured":"Charlton M, Everson GT, Flamm SL, et al.: Ledipasvir and Sofosbuvir plus Ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649\u201359","key":"10.3238\/arztebl.2017.0011_ref2","DOI":"10.1053\/j.gastro.2015.05.010"},{"doi-asserted-by":"crossref","unstructured":"Zimmermann T, Beckebaum S, Berg C, et al.: Empfehlungen zur antiviralen Therapie der chronischen Hepatitis C bei Patienten auf der Warteliste und nach Transplantation. Z Gastroenterol 2016; 54: 665\u201384","key":"10.3238\/arztebl.2017.0011_ref3","DOI":"10.1055\/s-0042-107360"},{"doi-asserted-by":"crossref","unstructured":"Younossi ZM, Stepanova M, Feld J, et al.: Sofosbuvir\/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J Hepatol 2016; 65: 33\u20139","key":"10.3238\/arztebl.2017.0011_ref4","DOI":"10.1016\/j.jhep.2016.02.042"},{"doi-asserted-by":"crossref","unstructured":"Sarrazin C, Berg T, Ross RS, et al.: Prophylaxe, Diagnostik und Therapie der Hepatitis C Virus (HCV) Infektion: German guidelines on the management of HCV infection. Z Gastroenterol 2010; 48: 289\u2013351","key":"10.3238\/arztebl.2017.0011_ref5","DOI":"10.1055\/s-0028-1110008"},{"doi-asserted-by":"crossref","unstructured":"Lange CM, Jacobson IM, Rice CM, Zeuzem S: Emerging therapies for the treatment of hepatitis C. EMBO Mol Med 2014; 6: 4\u201315.","key":"10.3238\/arztebl.2017.0011_ref6","DOI":"10.1002\/emmm.201303131"},{"doi-asserted-by":"crossref","unstructured":"Sarrazin C, H\u00e9zode C, Zeuzem S, Pawlotsky JM: Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 (Suppl 1): 88\u2013100","key":"10.3238\/arztebl.2017.0011_ref7","DOI":"10.1016\/S0168-8278(12)60010-5"},{"doi-asserted-by":"crossref","unstructured":"Deterding K, Spinner C, Schott E, et al.: Six weeks of ledipasvir\/sofosbuvir treatment of acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study. Lancet Infect Dis 2016; http:\/\/dx.doi.org\/10.1016\/S1473\u20133099(16)30408-X","key":"10.3238\/arztebl.2017.0011_ref8","DOI":"10.1055\/s-0036-1587008"},{"unstructured":"Robert-Koch-Institut-Ratgeber f\u00fcr \u00c4rzte: Hepatitis C. www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Merkblaetter\/Ratgeber_HepatitisC.html (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref9"},{"unstructured":"Zusammenfassung der Merkmale des Arzneimittels Harvoni (Fachinformation): http:\/\/ec.europa.eu\/health\/documents\/community-register\/2014\/20141117130011\/anx_130011_de.pdf (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref10"},{"unstructured":"Zusammenfassung der Merkmale des Arzneimittels Epclusa (Fachinformation): http:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160706135323\/anx_135323_de.pdf (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref11"},{"unstructured":"Zusammenfassung der Merkmale des Arzneimittels Viekirax (Fachinformation): http:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150115130406\/anx_130406_de.pdf (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref12"},{"unstructured":"Zusammenfassung der Merkmale des Arzneimittels Exviera (Fachinformation): http:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150115130446\/anx_130446_de.pdf (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref13"},{"unstructured":"Zusammenfassung der Merkmale des Arzneimittels Zepatier (Fachinformation): http:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160722135308\/anx_135308_de.pdf (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref14"},{"unstructured":"Zusammenfassung der Merkmale des Arzneimittels Sovaldi (Fachinformation): www.ema.europa.eu\/docs\/de_DE\/document_library\/EPAR_-_Product_Information\/human\/002798\/WC500160597.pdf (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref15"},{"unstructured":"Zusammenfassung der Merkmale des Arzneimittels Olysio (Fachinformation): http:\/\/ec.europa.eu\/health\/documents\/community-register\/2014\/20140514128513\/anx_128513_de.pdf (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref16"},{"unstructured":"Zusammenfassung der Merkmale des Arzneimittels Daklinza (Fachinformation): www.ema.europa.eu\/docs\/de_DE\/document_library\/EPAR_-_Product_Information\/human\/003768\/WC500172848.pdf (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref17"},{"doi-asserted-by":"crossref","unstructured":"Kowdley KV, Gordon SC, Reddy KR, et al.: Ledipasvir and sofosbuvir for\u00a08\u00a0or 12\u00a0weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879\u201388","key":"10.3238\/arztebl.2017.0011_ref18","DOI":"10.1056\/NEJMoa1402355"},{"doi-asserted-by":"crossref","unstructured":"Ferenci P, Bernstein D, Lalezari J, et al.: ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med\u00a02014; 370: 1983\u201392","key":"10.3238\/arztebl.2017.0011_ref19","DOI":"10.1056\/NEJMoa1402338"},{"doi-asserted-by":"crossref","unstructured":"Zeuzem S, Dusheiko GM, Salupere R, et al.: Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med\u00a02014; 370: 1993\u20132001","key":"10.3238\/arztebl.2017.0011_ref20","DOI":"10.1056\/NEJMoa1316145"},{"doi-asserted-by":"crossref","unstructured":"Nelson DR, Cooper JN, Lalezari JP, et al.: All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology\u00a02015; 61: 1127\u201335","key":"10.3238\/arztebl.2017.0011_ref21","DOI":"10.1002\/hep.27726"},{"doi-asserted-by":"crossref","unstructured":"H\u00e9zode C, Asselah T, Reddy KR, et al.: Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype\u00a04\u00a0chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385: 2502\u20139.","key":"10.3238\/arztebl.2017.0011_ref22","DOI":"10.1016\/S0140-6736(15)60159-3"},{"doi-asserted-by":"crossref","unstructured":"Zeuzem S, Ghalib R, Reddy KR, et al.: Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial. Ann Intern Med 2015; 163: 1\u201313","key":"10.3238\/arztebl.2017.0011_ref23","DOI":"10.7326\/M15-0785"},{"doi-asserted-by":"crossref","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, et al.: Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373: 2599\u201307","key":"10.3238\/arztebl.2017.0011_ref24","DOI":"10.1056\/NEJMoa1512610"},{"doi-asserted-by":"crossref","unstructured":"Foster GR, Afdhal N, Roberts SK, et al.: Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373: 2608\u201317","key":"10.3238\/arztebl.2017.0011_ref25","DOI":"10.1056\/NEJMoa1512612"},{"doi-asserted-by":"crossref","unstructured":"Afdhal N, Reddy KR, Nelson DR, et al.: Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483\u201393","key":"10.3238\/arztebl.2017.0011_ref26","DOI":"10.1056\/NEJMoa1316366"},{"doi-asserted-by":"crossref","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al.: Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211\u201321","key":"10.3238\/arztebl.2017.0011_ref27","DOI":"10.1056\/NEJMoa1306218"},{"doi-asserted-by":"crossref","unstructured":"Jacobson IM, Gordon SC, Kowdley KV, et al.: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867\u201377","key":"10.3238\/arztebl.2017.0011_ref28","DOI":"10.1056\/NEJMoa1214854"},{"doi-asserted-by":"crossref","unstructured":"Foster GR, Pianko S, Brown A, et al.: Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015; 149: 1462\u201370","key":"10.3238\/arztebl.2017.0011_ref29","DOI":"10.1053\/j.gastro.2015.07.043"},{"doi-asserted-by":"crossref","unstructured":"Sarrazin C, Zeuzem S: Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447\u201362","key":"10.3238\/arztebl.2017.0011_ref30","DOI":"10.1053\/j.gastro.2009.11.055"},{"doi-asserted-by":"crossref","unstructured":"Poordad F, Bennett M, Sepe TE, et al.: Ombitasvir\/paritaprevir\/r, dasabuvir, and sofosbuvir treatment of patients with HCV genotype 1-infection who failed a prior course of DAA therapy: the Quartz study. J Hepatol 2016; 64: 767\u20138","key":"10.3238\/arztebl.2017.0011_ref31","DOI":"10.1016\/S0168-8278(16)01496-3"},{"doi-asserted-by":"crossref","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al.: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889\u201398","key":"10.3238\/arztebl.2017.0011_ref32","DOI":"10.1056\/NEJMoa1402454"},{"doi-asserted-by":"crossref","unstructured":"Poordad F, Hezode C, Trinh R, et al.: ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973\u201382","key":"10.3238\/arztebl.2017.0011_ref33","DOI":"10.1056\/NEJMoa1402869"},{"doi-asserted-by":"crossref","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, et al.: Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373: 2618\u201328.","key":"10.3238\/arztebl.2017.0011_ref34","DOI":"10.1056\/NEJMoa1512614"},{"doi-asserted-by":"crossref","unstructured":"Manns M, Samuel D, Gane EJ, et al.: Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16: 685\u201397","key":"10.3238\/arztebl.2017.0011_ref35","DOI":"10.1016\/S1473-3099(16)00052-9"},{"unstructured":"University of Liverpool: HEP drug interaction. www.hep-druginteractions.org (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref36"},{"doi-asserted-by":"crossref","unstructured":"Pockros PJ, Reddy KR, Mantry PS, et al.: Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype\u00a01 infection and severe renal impairment or end-stage renal disease. Gastroenterology 2016; 150: 1590\u20138","key":"10.3238\/arztebl.2017.0011_ref37","DOI":"10.1053\/j.gastro.2016.02.078"},{"doi-asserted-by":"crossref","unstructured":"Roth D, Nelson DR, Bruchfeld A, et al.: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015; 386: 1537\u201345","key":"10.3238\/arztebl.2017.0011_ref38","DOI":"10.1016\/S0140-6736(15)00349-9"},{"doi-asserted-by":"crossref","unstructured":"Fontaine H, Lazarus A, Pol S, et al.: Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med 2015; 373: 1886\u20138","key":"10.3238\/arztebl.2017.0011_ref39","DOI":"10.1056\/NEJMc1505967"},{"unstructured":"Zusammenfassung der Merkmale des Arzneimittels Ribavirins (Fachinformation): www.ema.europa.eu\/docs\/de_DE\/document_library\/EPAR_-_Product_Information\/human\/001185\/WC500094137.pdf (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref40"},{"doi-asserted-by":"crossref","unstructured":"Platt L, Easterbrook P, Gower E, et al.: Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16: 797\u2013808","key":"10.3238\/arztebl.2017.0011_ref41","DOI":"10.1016\/S1473-3099(15)00485-5"},{"unstructured":"Bruggmann P, Berg T, \u00d8vrehus AL, et al.: Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21(Suppl 1): 5\u201333.","key":"10.3238\/arztebl.2017.0011_ref42"},{"doi-asserted-by":"crossref","unstructured":"Webster DP, Klenerman P, Dusheiko GM: Hepatitis C. Lancet 2015; 385: 1124\u201335","key":"10.3238\/arztebl.2017.0011_ref43","DOI":"10.1016\/S0140-6736(14)62401-6"},{"doi-asserted-by":"crossref","unstructured":"Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825\u201332","key":"10.3238\/arztebl.2017.0011_ref44","DOI":"10.1016\/S0140-6736(96)07642-8"},{"doi-asserted-by":"crossref","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(Suppl 1): 35\u201350","key":"10.3238\/arztebl.2017.0011_ref45","DOI":"10.1053\/j.gastro.2004.09.014"},{"doi-asserted-by":"crossref","unstructured":"Zeuzem S: Decade in review-HCV: hepatitis C therapy-a fast and competitive race. Nat Rev Gastroenterol Hepatol 2014; 11: 644\u20135","key":"10.3238\/arztebl.2017.0011_ref46","DOI":"10.1038\/nrgastro.2014.164"},{"doi-asserted-by":"crossref","unstructured":"Lamarre D, Anderson PC, Bailey M, et al.: An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186\u20139","key":"10.3238\/arztebl.2017.0011_ref47","DOI":"10.1038\/nature02099"},{"doi-asserted-by":"crossref","unstructured":"Swain MG, Lai MY, Shiffman ML, et al.: A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593\u2013601","key":"10.3238\/arztebl.2017.0011_ref48","DOI":"10.1053\/j.gastro.2010.07.009"},{"doi-asserted-by":"crossref","unstructured":"Simmons B, Saleem J, Hill A, Riley RD, Cooke GS: Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: A systematic review and meta-analysis. Clin Infect Dis 2016; 62: 683\u201394","key":"10.3238\/arztebl.2017.0011_ref49","DOI":"10.1093\/cid\/civ948"},{"doi-asserted-by":"crossref","unstructured":"Svarovskaia E, Martin R, Chodavarapu K, et al.: HCV reinfection cases in phase 3 studies of sofosbuvir. J Hepatol 2015; 62: 222\u20133","key":"10.3238\/arztebl.2017.0011_ref50","DOI":"10.1016\/S0168-8278(15)30077-5"},{"doi-asserted-by":"crossref","unstructured":"Grebely J, Prins M, Hellard M, et al.: Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012; 12: 408\u201314","key":"10.3238\/arztebl.2017.0011_ref51","DOI":"10.1016\/S1473-3099(12)70010-5"},{"unstructured":"Hill AM, Saleem J, Heath KA, Simmons B: Effects of sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with Hepatitis C infection. Hepatology 2014; 60: 218\u201319.","key":"10.3238\/arztebl.2017.0011_ref52"},{"doi-asserted-by":"crossref","unstructured":"Lee MH, Yang HI, Lu SN, et al.: Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206: 469\u201377","key":"10.3238\/arztebl.2017.0011_ref53","DOI":"10.1093\/infdis\/jis385"},{"doi-asserted-by":"crossref","unstructured":"Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F: Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790\u2013800","key":"10.3238\/arztebl.2017.0011_ref54","DOI":"10.1002\/hep.20659"},{"doi-asserted-by":"crossref","unstructured":"Afdhal N, Asselah T, Everson GT, et al.: HCV eradication results in reduction of hepatic venous pressure gradient 48 weeks after end of treatment. Final results of the study of sofosbuvir plus ribavirin in patients with cirrhosis and portal hypertension. J Hepatol 2016; 64: 221\u20132","key":"10.3238\/arztebl.2017.0011_ref55","DOI":"10.1016\/S0168-8278(16)00195-1"},{"doi-asserted-by":"crossref","unstructured":"Bochud PY, Cai T, Overbeck K, et al.: Genotype\u00a03\u00a0is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655\u201366","key":"10.3238\/arztebl.2017.0011_ref56","DOI":"10.1016\/j.jhep.2009.05.016"},{"doi-asserted-by":"crossref","unstructured":"Di Bisceglie AM: Hepatitis C and hepatocellular carcinoma. Hepatology\u00a01997; 26 (Suppl\u00a01): 34\u20138","key":"10.3238\/arztebl.2017.0011_ref57","DOI":"10.1002\/hep.510260706"},{"doi-asserted-by":"crossref","unstructured":"Roffi L, Redaelli A, Colloredo G, et al.: Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol\u00a02001; 13: 501\u20136","key":"10.3238\/arztebl.2017.0011_ref58","DOI":"10.1097\/00042737-200105000-00007"},{"doi-asserted-by":"crossref","unstructured":"Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S: Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int 2008; 28: 1332\u201343.","key":"10.3238\/arztebl.2017.0011_ref59","DOI":"10.1111\/j.1478-3231.2008.01896.x"},{"doi-asserted-by":"crossref","unstructured":"Welzel TM, Zeuzem S, Dumas EO, et al.: GARNET: High SVR rates following 8-week treatment with ombitasvir\/paritaprevir\/ritonavir + dasabuvir in patients with HCV genotype 1b infection. Presented at the European Association for the Study of the Liver Special Conference: New Perspectives in Hepatitis C Virus Infection \u2013The Roadmap for Cure, Paris, France on September 23\u201324, 2016: https:\/\/news.abbvie.com\/news\/abbvie-presents-data-on-eight-week-treatment-viekirax-ombitasvirparitaprevirritonavir-tablets-exviera-dasabuvir-tablets-in-patients-with-genotype-1b-chronic-hepatitis-c.htm (last accessed on 9 October 2016)","key":"10.3238\/arztebl.2017.0011_ref60","DOI":"10.14309\/00000434-201610001-00888"},{"doi-asserted-by":"crossref","unstructured":"Abergel A, Metivier S, Samuel D, et al.: Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 2016; 64:1049\u201356","key":"10.3238\/arztebl.2017.0011_ref61","DOI":"10.1002\/hep.28706"},{"doi-asserted-by":"crossref","unstructured":"H\u00e9zode C, Abergel A, Chas J, et al.: Sustained virologic response to daclatasvir and sofosbuvir, with or without ribavirin, among patients in the French daclatasvir ATU programme infected with HCV genotypes 4, 5 and 6. J Hepatol 2016; 64: 755","key":"10.3238\/arztebl.2017.0011_ref62","DOI":"10.1016\/S0168-8278(16)01471-9"},{"doi-asserted-by":"crossref","unstructured":"Buti M, Calleja JL, Forns X, et al.: Simeprevir plus sofosbuvir for hepatitis C virus genotype 4 infection: a phase 3, open-label study. J Hepatol 2016; 64: 220\u20131","key":"10.3238\/arztebl.2017.0011_ref63","DOI":"10.1016\/S0168-8278(16)00193-8"},{"doi-asserted-by":"crossref","unstructured":"Hedskog C, Doehle B, Chodavarapu K, et al.: Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir\/ribavirin. Hepatology 2015; 61: 471\u201380","key":"10.3238\/arztebl.2017.0011_ref64","DOI":"10.1002\/hep.27361"},{"doi-asserted-by":"crossref","unstructured":"Susser S, Dietz J, Barak M, et al.: Prevalence and clinical importance of hepatitis C virus genotype 2k\/1b chimeras. J Hepatol 2016: 64: 136.","key":"10.3238\/arztebl.2017.0011_ref65","DOI":"10.1016\/S0168-8278(16)01638-X"},{"doi-asserted-by":"crossref","unstructured":"Abergel A, Asselah T, Metivier S, et al.: Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis 2016; 16: 459\u201364","key":"10.3238\/arztebl.2017.0011_ref66","DOI":"10.1016\/S1473-3099(15)00529-0"},{"doi-asserted-by":"crossref","unstructured":"Gane EJ, Hyland RH, An D, et al.: Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015; 149: 1454\u201361","key":"10.3238\/arztebl.2017.0011_ref67","DOI":"10.1053\/j.gastro.2015.07.063"},{"doi-asserted-by":"crossref","unstructured":"Sarrazin C: The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016; 64: 486\u2013504","key":"10.3238\/arztebl.2017.0011_ref68","DOI":"10.1016\/j.jhep.2015.09.011"},{"doi-asserted-by":"crossref","unstructured":"Vermehren J, Susser S, Dietz J, et al.: Retreatment of patients who failed DAA-combination therapies: real-world experience from a large hepatitis C resistance database. J Hepatol 2016; 64: 188","key":"10.3238\/arztebl.2017.0011_ref69","DOI":"10.1016\/S0168-8278(16)00128-8"},{"doi-asserted-by":"crossref","unstructured":"Gane E, Poordad F, Wang S, et al.: High Efficacy of ABT-493 and ABT-530 in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology 2016; 151: :651\u20139.","key":"10.3238\/arztebl.2017.0011_ref70","DOI":"10.1053\/j.gastro.2016.07.020"},{"doi-asserted-by":"crossref","unstructured":"Gane EJ, Schwabe C, Hyland RH, et al.: Efficacy of the combination of Sofosbuvir, Velpatasvir, and the NS3\/4A Protease Inhibitor GS-9857 in treatment-na\u00efve or previously treated patients with hepatitis C virus genotype 1 or 3 infections. Gastroenterology 2016; 151: 448\u201356","key":"10.3238\/arztebl.2017.0011_ref71","DOI":"10.1053\/j.gastro.2016.05.021"},{"doi-asserted-by":"crossref","unstructured":"Gane EJ, Pianko S, Roberts SK, et al.: High efficacy of an 8-week 3-drug regimen of grazoprevir\/MK-8408\/MK-3682 in HCV genotype 1, 2 and 3-infected patients: SVR24 data from the phase 2 C-CREST 1 and 2 studies. J Hepatol 2016; 64: 759","key":"10.3238\/arztebl.2017.0011_ref72","DOI":"10.1016\/S0168-8278(16)01479-3"},{"doi-asserted-by":"crossref","unstructured":"Poynard T, Morra R, Ingiliz P, et al.: Biomarkers of liver fibrosis. Adv Clin Chem 2008; 46: 131\u201360","key":"10.3238\/arztebl.2017.0011_ref73","DOI":"10.1016\/S0065-2423(08)00404-6"},{"doi-asserted-by":"crossref","unstructured":"Friedrich-Rust M, Poynard T, Castera L: Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol 2016; 13: 402\u201311","key":"10.3238\/arztebl.2017.0011_ref74","DOI":"10.1038\/nrgastro.2016.86"},{"doi-asserted-by":"crossref","unstructured":"Feld JJ, Moreno C, Trinh R, et al.: Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir\/paritaprevir\/r and dasabuvir for 12 weeks. J Hepatol 2016; 64: 301\u20137","key":"10.3238\/arztebl.2017.0011_ref75","DOI":"10.1016\/j.jhep.2015.10.005"},{"doi-asserted-by":"crossref","unstructured":"Lawitz E, Matusow G, DeJesus E, et al.: Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016; 64: 360\u20139","key":"10.3238\/arztebl.2017.0011_ref76","DOI":"10.1002\/hep.28422"},{"doi-asserted-by":"crossref","unstructured":"Welzel T, Petersen J, Herzer K, et al.: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016 [epub ahera of print].","key":"10.3238\/arztebl.2017.0011_ref77","DOI":"10.1136\/gutjnl-2016-312444"},{"unstructured":"Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS): Therapie der chronischen Hepatitis C \u2013 Addendum zur S3 Leitlinie Februar 2015. www.dgvs.de\/leitlinien\/therapie-der-chronischen-hepatitis-c\/ (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref78"},{"unstructured":"European Association for the Study of the Liver (EASL): EASL recommendations on treatment of Hepatitis C 2016. www.easl.eu\/medias\/cpg\/HCV2016\/English-report.pdf (last accessed on 9 October 2016).","key":"10.3238\/arztebl.2017.0011_ref79"},{"unstructured":"American Association for the Study of Liver Disease (AASLD) and Infectious Diseases Society of America (IDSA): HCV guidance\u2014 recommendations for testing, managing, and treating Hepatitis C. www.hcvguidelines.org\/full-report\/retreatment-persons-whom-prior-therapy-has-failed (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref80"},{"doi-asserted-by":"crossref","unstructured":"Reddy KR, Bourli\u00e8re M, Sulkowski M, et al.: Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology\u00a02015; 62: 79\u201386","key":"10.3238\/arztebl.2017.0011_ref81","DOI":"10.1002\/hep.27826"},{"unstructured":"Kwo P, Gane E, Peng C-Y, et al.: Effectiveness of Elbasvir and Grazoprevir combination, with or without Ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 2016; [epub ahera of print].","key":"10.3238\/arztebl.2017.0011_ref82"},{"doi-asserted-by":"crossref","unstructured":"Leroy V, Angus P, Bronowicki JP, et al.: Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype\u00a03\u00a0and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 2016; 63: 1430\u201341","key":"10.3238\/arztebl.2017.0011_ref83","DOI":"10.1002\/hep.28473"},{"doi-asserted-by":"crossref","unstructured":"Bunchorntavakul C, Reddy KR: Treat chronic hepatitis C virus infection in decompensated cirrhosis \u2013 pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepat 2016; 23: 408\u201318","key":"10.3238\/arztebl.2017.0011_ref84","DOI":"10.1111\/jvh.12534"},{"doi-asserted-by":"crossref","unstructured":"Welker M, Luhne S, Lange CM, et al.: Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin\/sofosbuvir treatment. J Hepatol 2016; 64: 790\u20139","key":"10.3238\/arztebl.2017.0011_ref85","DOI":"10.1016\/j.jhep.2015.11.034"},{"doi-asserted-by":"crossref","unstructured":"Zhang YQ, Guo JS: Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol\u00a02015; 21: 3860\u20136","key":"10.3238\/arztebl.2017.0011_ref86","DOI":"10.3748\/wjg.v21.i13.3860"},{"doi-asserted-by":"crossref","unstructured":"Kwo PY, Mantry PS, Coakley E, et al.: An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med\u00a02014; 371: 2375\u201382","key":"10.3238\/arztebl.2017.0011_ref87","DOI":"10.1056\/NEJMoa1408921"},{"doi-asserted-by":"crossref","unstructured":"Pungpapong S, Aqel B, Leise M, et al.: Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology\u00a02015; 61: 1880\u20136","key":"10.3238\/arztebl.2017.0011_ref88","DOI":"10.1002\/hep.27770"},{"doi-asserted-by":"crossref","unstructured":"Saxena V, Koraishy FM, Sise ME, et al.: Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 2016; 36: 807\u2013816","key":"10.3238\/arztebl.2017.0011_ref89","DOI":"10.1111\/liv.13102"},{"doi-asserted-by":"crossref","unstructured":"Desnoyer A, Pospai D, L\u00ea MP, et al.: Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 2016; 65: 40\u20137","key":"10.3238\/arztebl.2017.0011_ref90","DOI":"10.1016\/j.jhep.2016.02.044"},{"doi-asserted-by":"crossref","unstructured":"Naggie S, Cooper C, Saag M, et al.: Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 705\u201313","key":"10.3238\/arztebl.2017.0011_ref91","DOI":"10.1056\/NEJMoa1501315"},{"doi-asserted-by":"crossref","unstructured":"Wyles DL, Ruane PJ, Sulkowski MS, et al.: Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 714\u201325","key":"10.3238\/arztebl.2017.0011_ref92","DOI":"10.1056\/NEJMoa1503153"},{"doi-asserted-by":"crossref","unstructured":"Sulkowski MS, Eron JJ, Wyles D, et al.: Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313: 1223\u201331","key":"10.3238\/arztebl.2017.0011_ref93","DOI":"10.1001\/jama.2015.1328"},{"doi-asserted-by":"crossref","unstructured":"Rockstroh JK, Nelson M, Katlama C, et al.: Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2: e319\u201327. Erratum in: Lancet HIV 2015; 2: e416. Lancet HIV 2015; 2: e316.","key":"10.3238\/arztebl.2017.0011_ref94","DOI":"10.1016\/S2352-3018(15)00114-9"},{"doi-asserted-by":"crossref","unstructured":"Gane EJ, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG: Ledipasvir and sofosbuvir for HCV-infection in patients coinfected with HBV. Antivir Ther 2016; Jul 1. [Epub ahead of print].","key":"10.3238\/arztebl.2017.0011_ref95","DOI":"10.3851\/IMP3066"},{"doi-asserted-by":"crossref","unstructured":"Yeung CY, Lee HC, Chan WT, Jiang CB, Chang SW, Chuang CK: Vertical transmission of hepatitis C virus: Current knowledge and perspectives. World J Hepatol 2014; 6: 643\u201351","key":"10.3238\/arztebl.2017.0011_ref96","DOI":"10.4254\/wjh.v6.i9.643"},{"doi-asserted-by":"crossref","unstructured":"Jara P, Resti M, Hierro L, et al.: Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis\u00a02003; 36: 275\u201380","key":"10.3238\/arztebl.2017.0011_ref97","DOI":"10.1086\/345908"},{"doi-asserted-by":"crossref","unstructured":"Schwarz K, Murray KF, Rosenthal P, et al.: High rates of SVR12 in adolescents treated with the combination of ledipasvir\/sofosbuvir. J Hepatol 2016, 64: 184.","key":"10.3238\/arztebl.2017.0011_ref98","DOI":"10.1016\/S0168-8278(16)01697-4"},{"unstructured":"Gilead Sciences: Safety and efficacy of Ledipasvir\/Sofosbuvir fixed dose combination +\/-Ribavirin in adolescents and children with chronic HCV-infection. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02249182 (last accessed on 20 August 2016).","key":"10.3238\/arztebl.2017.0011_ref99"},{"doi-asserted-by":"crossref","unstructured":"Shouval D, Shibolet O: Immunosuppression and HBV reactivation. Semin Liver Dis 2013; 33: 167\u2013177","key":"10.3238\/arztebl.2017.0011_ref100","DOI":"10.1055\/s-0033-1345722"},{"doi-asserted-by":"crossref","unstructured":"Afdhal N, Bacon B, Curry M, et al.: No effect of proton pump inhibitor (PPI) use on SVR with ledipasvir\/sofosbuvir (LDV\/SOF): Real world data from 2034 genotype 1 patients in the Trio network. J Hepatol 2016: 64: 222\u20133.","key":"10.3238\/arztebl.2017.0011_ref101","DOI":"10.1016\/S0168-8278(16)00196-3"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T10:07:14Z","timestamp":1638871634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,9]]},"references-count":101,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2017.0011","relation":{},"ISSN":["1866-0452"],"issn-type":[{"type":"electronic","value":"1866-0452"}],"subject":[],"published":{"date-parts":[[2017,1,9]]}}}